[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621917":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":25,"locations":30,"responsibleParty":69,"collaborators":73,"id":77,"slug":78,"hasResults":79,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":79,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":25,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":25,"overallStatus":98,"whyStopped":25,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"University Hospital, Motol","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"TIR group","ACTIVE_COMPARATOR","Participants in this group will follow the current standard international clinical guidelines, targeting a glycemic range of 3.9-10.0 mmol\u002FL (70-180 mg\u002FdL). They will receive the same level of structured multidisciplinary education and clinical follow-up as the intervention group, but calibrated to the standard 70-180 mg\u002FdL range.",[13],"Other: Structured Diabetes Education",{"label":15,"type":16,"description":17,"interventionNames":18},"TING group","EXPERIMENTAL","Participants in this group will target a tighter glycemic range of 3.9-7.8 mmol\u002FL (70-140 mg\u002FdL). Their CGM and insulin pump settings will be adjusted by their physician to support this narrower range. Participants will receive structured education focused on achieving this tighter target.",[13,19],"Other: Automated Insulin Delivery (AID) System Adjustment",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"Structured Diabetes Education","A comprehensive standardized guideline will be provided to recruiting physicians from all centers, including the points below:\n\n1. Understanding CGM data and trend interpretation\n2. TIR or TING concepts according to randomization, target range, consequences of hypoglycemia and hyperglycemia\n3. Recognizing and management of hypoglycemia\n4. Recognizing and management of hyperglycemia\n5. Setting and adjusting of glycemic targets, alarms in CGM and insulin pumps, and insulin doses based on randomisation\n6. Emotional coping strategies and involving family support",[15,9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Automated Insulin Delivery (AID) System Adjustment","For the TING group, CGM hyperglycemia target settings will be lowered by at-least 10% from the baseline values. The extent of the adjustment will be at the discretion of the attending physician",[15],[31,46,56],{"facility":32,"status":25,"city":33,"state":25,"zip":25,"country":34,"countryCode":25,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Motol University Hospital","Prague","Czechia",{"type":36,"coordinates":37},"Point",[38,39],14.42076,50.08804,{"lat":39,"lon":38},[42],{"name":43,"role":44,"phone":25,"phoneExt":25,"email":45},"Shenali Amaratunga","CONTACT","shenali.amaratunga@fnmotol.cz",{"facility":47,"status":25,"city":48,"state":25,"zip":25,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":55,"contacts":25},"Schneider Children's Medical Center of Israel","Petah Tikva","Israel","IL",{"type":36,"coordinates":52},[53,54],34.88747,32.08707,{"lat":54,"lon":53},{"facility":57,"status":25,"city":58,"state":25,"zip":25,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":65,"contacts":66},"Medical University of Warsaw","Warsaw","Poland","PL",{"type":36,"coordinates":62},[63,64],21.01178,52.22977,{"lat":64,"lon":63},[67],{"name":68,"role":44,"phone":25,"phoneExt":25,"email":25},"Agnieszka Szypowska",{"type":70,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Zdeněk Šumník","MD, PhD",[74,76],{"name":75,"class":6},"Schneider Children's Medical Center, Israel",{"name":57,"class":6},"100621917","time-in-range-vs-time-in-normal-glycemia-for-better-glycemic-control-100621917",false,"NCT07376850","Time in rANge vs. Time in nOrmal Glycemia for Better Glycemic Control","TANGO","Inclusion Criteria:\n\n* Diagnosis of T1D per ADA criteria\n* Age 5.0-17.99 at the start of study\n* CGM use \\>70% of the time during the month prior to enrollment\n* Maximum HbA1c of 86mmol\u002Fmol (10% in DCCT)\n\nExclusion Criteria:\n\n* No concurrent illnesses impacting glycemia\n* No treatments impacting glycemia\n* Severe hypoglycemia documented in the 60 day period leading up to patient recruitment\n* Current participation in any other interventional study\n* Any significant diseases \u002F conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise participant's safety\n* Female subject who is pregnant or lactating or planning to become pregnant within the planned study duration","ALL","5 Years","18 Years",{"count":88,"type":89},120,"ESTIMATED","INTERVENTIONAL",[92],"NA","The TANGO study is a 12-month study involving 120 children and adolescents with Type 1 Diabetes (T1D) across the Czech Republic, Israel, and Poland who use automated insulin delivery (AID) systems.\n\nCurrently, the global standard for diabetes management is \"Time in Range\" (TIR), which aims to keep blood sugar levels between 70-180 mg\u002FdL. However, newer technologies like AID systems may now allow for a tighter, more physiological goal called \"Time in Normal Glycemia\" (TING), which targets a range of 70-140 mg\u002FdL.\n\nThis study will randomly assign participants to follow either the standard TIR target or the tighter TING target to see if the narrower range improves overall blood sugar control and HbA1c without increasing the risk of hypoglycemia, family stress, or daily treatment burden.\n\nBy comparing these two approaches, researchers hope to determine if clinical guidelines should be updated to reflect a more precise glucose target for children and adolescents worldwide",[95,96,97],"Diabetes","Diabetes (DM)","Diabetes Type 1","NOT_YET_RECRUITING","2026-01-21",{"date":101,"type":102},"2026-01-29","ACTUAL",{"date":104,"type":89},"2026-01",{"date":106,"type":89},"2026-06",{"name":5,"class":6},3]